Tisagenlecleucel_CellTherapyReleaseQualityChecker

Tisagenlecleucel Cell Therapy Release Checker

ADC Advanced therapy Biopharma BiopharmaExtended Bispecific CSV→JSON CellTherapy FDC

Tisagenlecleucel Cell Therapy Release Checker — Tisagenlecleucel (CAR-T therapy)

ℹ️ Utility checks critical release parameters of tisagenlecleucel (Kymriah):
• Viability (≥70%)
• % CAR-positive cells (20-60%)
• Total viable CAR+ cells (≥1.0E6)
• % CD3+ T-cells (≥60%)
• B-cell contamination (≤5%)
• Mycoplasma (Negative)
• Endotoxins (≤5 EU/dose)
• Vector copy number (0.5-5.0)
• Potency (IFN-gamma ≥1000 pg/mL)

⚠️ CRITICAL: This is a personalized product! Error is unacceptable.
Mycoplasma or low viability leads to batch rejection.

Usage:
TisagenlecleucelQualityChecker.exe → demo mode (console output)
TisagenlecleucelQualityChecker.exe input.csv output.json → evaluate your data

Input format:
BatchNumber,ViabilityPercent,CARPositiveCellsPercent,TotalViableCARPositiveCells,CD3PositiveCellsPercent,BCellContaminationPercent,MycoplasmaTest,EndotoxinsEUPerDose,VectorCopyNumber,PotencyIFNg_pg_ml,PatientID

Example (mycoplasma: 0=Neg, 1=Pos):
KYM-2026-PAT-001,85.0,45.0,1.5E7,92.0,1.0,0,2.0,2.5,1500.0,PAT-12345

— WHY IS THIS NEEDED?
Tisagenlecleucel (Kymriah) is the first approved CAR-T gene therapy:
• Uses patient's own T-cells modified to attack CD19+ tumor cells
• Used for relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and lymphoma
• Manufacturing process is individual for each patient (autologous)
• Requires strictest quality control due to risks of cytokine release syndrome and neurotoxicity

⚠️ CRITICAL:
• Viability ≥70% — dead cells do not work and may cause inflammation
• CAR+ cells 20-60% — determines product specificity against tumor
• Dose (cell count) — must be sufficient to achieve remission
• Absence of mycoplasma — absolute safety requirement
• VCN (vector copies) — too high increases oncogenesis risk, too low reduces efficacy
• Potency (functional activity) — confirms cells can kill tumor

Key features:
• Identity check (CAR+, CD3+)
• Purity check (B-cell removal)
• Safety check (mycoplasma, endotoxins, VCN)
• Potency check (functional assay)
• Link to Patient ID (personalized medicine)

Critical parameters:
• Viability: ≥70.0%
• CAR-positive cells: 20.0–60.0%
• Total viable CAR+ cells: ≥1.0E6
• CD3+ cells: ≥60.0%
• B-cell contamination: ≤5.0%
• Mycoplasma: Negative (0)
• Endotoxins: ≤5.0 EU/dose
• VCN: 0.5–5.0 copies/cell
• Potency (IFN-gamma): ≥1000 pg/mL

💡 Usage tips:
1. Analysis performed by Flow Cytometry
2. VCN determined by qPCR
3. Potency measured in co-culture assay with target cells
4. Product stored cryopreserved in liquid nitrogen
5. Any deviation in sterility leads to immediate rejection, as there is no alternative batch for this patient

⚠️ Note: Unlike traditional drugs, CAR-T therapy is a "living drug". Quality depends not only on chemical composition but also on biological activity and cell viability. Each product is unique and intended for only one specific patient.

input.csv

BatchNumber,ViabilityPercent,CARPositiveCellsPercent,TotalViableCARPositiveCells,CD3PositiveCellsPercent,BCellContaminationPercent,MycoplasmaTest,EndotoxinsEUPerDose,VectorCopyNumber,PotencyIFNg_pg_ml,PatientID
KYM-2026-PAT-001,85.0,45.0,1.5E7,92.0,1.0,0,2.0,2.5,1500.0,PAT-12345
KYM-2026-PAT-002,75.0,30.0,8.0E6,85.0,2.0,0,3.5,1.8,1200.0,PAT-67890
KYM-2026-PAT-003,90.0,50.0,2.0E7,95.0,0.5,0,1.0,3.0,2000.0,PAT-11223

Tisagenlecleucel_CellTherapyReleaseQualityChecker — Documentation

Bilingual RU/EN URS & FS. Source: input.csv and *.description.txt. Package folder: Biopharmaceuticals Extended QC Suite.

Utility

Tisagenlecleucel_CellTherapyReleaseQualityChecker

Package

Biopharmaceuticals Extended QC Suite

CSV fields

Interface

CSV → JSON

Utility description

Tisagenlecleucel Cell Therapy Release Checker — Tisagenlecleucel (CAR-T therapy)

ℹ️  Utility checks critical release parameters of tisagenlecleucel (Kymriah):
    • Viability (≥70%)
    • % CAR-positive cells (20-60%)
    • Total viable CAR+ cells (≥1.0E6)
    • % CD3+ T-cells (≥60%)
    • B-cell contamination (≤5%)
    • Mycoplasma (Negative)
    • Endotoxins (≤5 EU/dose)
    • Vector copy number (0.5-5.0)
    • Potency (IFN-gamma ≥1000 pg/mL)

⚠️  CRITICAL: This is a personalized product! Error is unacceptable.
    Mycoplasma or low viability leads to batch rejection.

Usage:
  TisagenlecleucelQualityChecker.exe                            → demo mode (console output)
  TisagenlecleucelQualityChecker.exe input.csv output.json      → evaluate your data

Input format:
BatchNumber,ViabilityPercent,CARPositiveCellsPercent,TotalViableCARPositiveCells,CD3PositiveCellsPercent,BCellContaminationPercent,MycoplasmaTest,EndotoxinsEUPerDose,VectorCopyNumber,PotencyIFNg_pg_ml,PatientID

Example (mycoplasma: 0=Neg, 1=Pos):
  KYM-2026-PAT-001,85.0,45.0,1.5E7,92.0,1.0,0,2.0,2.5,1500.0,PAT-12345

— WHY IS THIS NEEDED?
Tisagenlecleucel (Kymriah) is the first approved CAR-T gene therapy:
• Uses patient's own T-cells modified to attack CD19+ tumor cells
• Used for relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and lymphoma
• Manufacturing process is individual for each patient (autologous)
• Requires strictest quality control due to risks of cytokine release syndrome and neurotoxicity

⚠️  CRITICAL:
• Viability ≥70% — dead cells do not work and may cause inflammation
• CAR+ cells 20-60% — determines product specificity against tumor
• Dose (cell count) — must be sufficient to achieve remission
• Absence of mycoplasma — absolute safety requirement
• VCN (vector copies) — too high increases oncogenesis risk, too low reduces efficacy
• Potency (functional activity) — confirms cells can kill tumor

Key features:
• Identity check (CAR+, CD3+)
• Purity check (B-cell removal)
• Safety check (mycoplasma, endotoxins, VCN)
• Potency check (functional assay)
• Link to Patient ID (personalized medicine)

Critical parameters:
• Viability: ≥70.0%
• CAR-positive cells: 20.0–60.0%
• Total viable CAR+ cells: ≥1.0E6
• CD3+ cells: ≥60.0%
• B-cell contamination: ≤5.0%
• Mycoplasma: Negative (0)
• Endotoxins: ≤5.0 EU/dose
• VCN: 0.5–5.0 copies/cell
• Potency (IFN-gamma): ≥1000 pg/mL

💡 Usage tips:
1. Analysis performed by Flow Cytometry
2. VCN determined by qPCR
3. Potency measured in co-culture assay with target cells
4. Product stored cryopreserved in liquid nitrogen
5. Any deviation in sterility leads to immediate rejection, as there is no alternative batch for this patient

⚠️ Note: Unlike traditional drugs, CAR-T therapy is a "living drug". Quality depends not only on chemical composition but also on biological activity and cell viability. Each product is unique and intended for only one specific patient.

URS & FS — User Requirements and Functional Specification

This document describes the controlled interface and behaviour of Tisagenlecleucel_CellTherapyReleaseQualityChecker for Tisagenlecleucel Cell Therapy Release Checker.

Domain limits URS input.csv FS IQ/OQ/PQ

Portal packages

Biopharmaceuticals Extended QC Suite, Biopharmaceuticals Core QC Suite, Global/API coverage extension, Immunology QC Suite, LabEx QC laboratory utilities, Lumex QC instrument utilities, World API/FDC extension

ADCAdvanced therapyBiopharmaBiopharmaExtendedBispecificCSV→JSONCellTherapyFDCImmunologyMissingAPIOncologyPlasma-derivedQCURS & FSmAbP2

Domain limits and critical parameters

Key fragments from the source description are shown below. Before production use, limits must be verified against the approved specification, registration dossier and local SOPs.

ℹ️ Utility checks critical release parameters of tisagenlecleucel (Kymriah):
• Viability (≥70%)
• Total viable CAR+ cells (≥1.0E6)
• % CD3+ T-cells (≥60%)
• B-cell contamination (≤5%)
• Endotoxins (≤5 EU/dose)
• Potency (IFN-gamma ≥1000 pg/mL)
⚠️ CRITICAL: This is a personalized product! Error is unacceptable.
BatchNumber,ViabilityPercent,CARPositiveCellsPercent,TotalViableCARPositiveCells,CD3PositiveCellsPercent,BCellContaminationPercent,MycoplasmaTest,EndotoxinsEUPerDose,VectorCopyNumber,PotencyIFNg_pg_ml,PatientID
⚠️ CRITICAL:
• Viability ≥70% — dead cells do not work and may cause inflammation
• Safety check (mycoplasma, endotoxins, VCN)
• Potency check (functional assay)
Critical parameters:
• Viability: ≥70.0%
• Total viable CAR+ cells: ≥1.0E6
• CD3+ cells: ≥60.0%
• B-cell contamination: ≤5.0%

URS — User Requirements Specification

ID	Requirement	Criticality	Acceptance criterion
URS-001	The utility shall accept an input.csv file for Tisagenlecleucel Cell Therapy Release Checker with headers defined in the data contract.	High	The file is processed without manual header editing.
URS-002	The utility shall perform deterministic QC evaluation without machine learning and without probabilistic conformance decisions.	High	Identical input data, rule version and configuration produce reproducible results.
URS-003	The utility shall validate mandatory fields, data types, ranges, units and domain plausibility.	High	Schema, conversion and range errors are explicitly reported.
URS-004	The utility shall apply domain limits and rules from the description, approved specification, registration dossier and local SOPs.	High	Each check has PASS/WARNING/FAIL and a clear message.
URS-005	The utility shall generate output.json with machine-readable results, source values, warnings, failures and critical findings.	High	JSON is suitable for LIMS/ELN/MES integration and QA/QC review.
URS-006	The utility shall preserve traceability between batch/sample, input file, applied rules and final status.	High	Output contains identifiers, checked parameters and audit metadata.
URS-007	The documentation shall support IQ/OQ/PQ, CSV/CSA and review by internal QA or inspectors.	Medium	URS, FS, input/output contract and test scenarios are supplied with the utility.
URS-008	The utility shall be used as a QC decision-support tool and not as a substitute for approved specifications and QA/QP release decision.	Medium	Documentation states change control and limit-verification expectations.

input.csv contract

#	Field	Type	Sample	Purpose
1	`BatchNumber`	string / controlled vocabulary	`KYM-2026-PAT-001`	Batch or lot identifier used for traceability.
2	`ViabilityPercent`	decimal	`85.0`	Controlled input parameter for deterministic QC rules.
3	`CARPositiveCellsPercent`	decimal	`45.0`	Controlled input parameter for deterministic QC rules.
4	`TotalViableCARPositiveCells`	decimal	`1.5E7`	Controlled input parameter for deterministic QC rules.
5	`CD3PositiveCellsPercent`	decimal	`92.0`	Controlled input parameter for deterministic QC rules.
6	`BCellContaminationPercent`	decimal	`1.0`	Controlled input parameter for deterministic QC rules.
7	`MycoplasmaTest`	decimal	`0`	Controlled input parameter for deterministic QC rules.
8	`EndotoxinsEUPerDose`	decimal	`2.0`	Microbiological/endotoxin parameter relevant to safety.
9	`VectorCopyNumber`	decimal	`2.5`	Controlled input parameter for deterministic QC rules.
10	`PotencyIFNg_pg_ml`	decimal	`1500.0`	Quantitative content/potency; critical release parameter.
11	`PatientID`	string / controlled vocabulary	`PAT-12345`	Controlled input parameter for deterministic QC rules.

BatchNumber,ViabilityPercent,CARPositiveCellsPercent,TotalViableCARPositiveCells,CD3PositiveCellsPercent,BCellContaminationPercent,MycoplasmaTest,EndotoxinsEUPerDose,VectorCopyNumber,PotencyIFNg_pg_ml,PatientID
KYM-2026-PAT-001,85.0,45.0,1.5E7,92.0,1.0,0,2.0,2.5,1500.0,PAT-12345
KYM-2026-PAT-002,75.0,30.0,8.0E6,85.0,2.0,0,3.5,1.8,1200.0,PAT-67890
KYM-2026-PAT-003,90.0,50.0,2.0E7,95.0,0.5,0,1.0,3.0,2000.0,PAT-11223

Input validation rules

ID	Field	Rule	Criticality
VR-001	`BatchNumber`	The field shall match an approved dictionary or accepted string representation.	High
VR-002	`ViabilityPercent`	The value shall be numeric, non-empty and domain-plausible for the approved specification.	High
VR-003	`CARPositiveCellsPercent`	The value shall be numeric, non-empty and domain-plausible for the approved specification.	High
VR-004	`TotalViableCARPositiveCells`	The value shall be numeric, non-empty and domain-plausible for the approved specification.	Medium
VR-005	`CD3PositiveCellsPercent`	The value shall be numeric, non-empty and domain-plausible for the approved specification.	Medium
VR-006	`BCellContaminationPercent`	The value shall be numeric, non-empty and domain-plausible for the approved specification.	Medium
VR-007	`MycoplasmaTest`	The value shall be numeric, non-empty and domain-plausible for the approved specification.	Medium
VR-008	`EndotoxinsEUPerDose`	The value shall be numeric, non-empty and domain-plausible for the approved specification.	High
VR-009	`VectorCopyNumber`	The value shall be numeric, non-empty and domain-plausible for the approved specification.	Medium
VR-010	`PotencyIFNg_pg_ml`	The value shall be numeric, non-empty and domain-plausible for the approved specification.	High
VR-011	`PatientID`	The field shall match an approved dictionary or accepted string representation.	Medium

FS — Functional Specification

ID	Function	Implementation
FS-001	CLI execution	Support execution modes: demo mode without arguments and production mode input.csv output.json.
FS-002	CSV import	Read input.csv in UTF-8/CSV-compatible format and validate header and expected columns.
FS-003	Schema validation	Check mandatory fields, column count, unknown key fields and empty mandatory values.
FS-004	Type conversion	Convert numeric, flag and text values; invalid format is recorded as a row-level error.
FS-005	Domain rule engine	Apply rules for Tisagenlecleucel Cell Therapy Release Checker, including critical limits from the description and approved specification.
FS-006	Status aggregation	Produce final status: FAIL for critical failure, WARNING for non-critical deviation, PASS for conformance.
FS-007	JSON export	Write output.json with detailed checks, source values, warnings, failures and critical findings.
FS-008	Audit support	Keep result structure suitable for review, deviation investigation and calculation reproduction.
FS-009	Integration contract	Support the scenario LIMS/ELN/MES → input.csv → utility → output.json → portal/admin review.
FS-010	Fallback mapping	For a single API or modality, use this specialized utility together with applicable Lumex/LabEx instrumental checks.
FS-011	Error handling	Return explicit messages for missing file, empty CSV, invalid schema, output write failure and invalid format.

Example output.json

{
  "utilityId": "tisagenlecleucel-cell-therapy-release-quality-checker",
  "utilityFolder": "Tisagenlecleucel_CellTherapyReleaseQualityChecker",
  "package": "Biopharmaceuticals Extended QC Suite",
  "overallStatus": "PASS|WARNING|FAIL",
  "sourceFile": "input.csv",
  "processedAtUtc": "2026-07-02T00:00:00Z",
  "checks": [
    {
      "parameter": "BatchNumber",
      "value": "KYM-2026-PAT-001",
      "status": "PASS|WARNING|FAIL",
      "message": "Deterministic rule-based check result",
      "ruleReference": "FS-RULE-001"
    },
    {
      "parameter": "ViabilityPercent",
      "value": "85.0",
      "status": "PASS|WARNING|FAIL",
      "message": "Deterministic rule-based check result",
      "ruleReference": "FS-RULE-002"
    },
    {
      "parameter": "CARPositiveCellsPercent",
      "value": "45.0",
      "status": "PASS|WARNING|FAIL",
      "message": "Deterministic rule-based check result",
      "ruleReference": "FS-RULE-003"
    },
    {
      "parameter": "TotalViableCARPositiveCells",
      "value": "1.5E7",
      "status": "PASS|WARNING|FAIL",
      "message": "Deterministic rule-based check result",
      "ruleReference": "FS-RULE-004"
    },
    {
      "parameter": "CD3PositiveCellsPercent",
      "value": "92.0",
      "status": "PASS|WARNING|FAIL",
      "message": "Deterministic rule-based check result",
      "ruleReference": "FS-RULE-005"
    },
    {
      "parameter": "BCellContaminationPercent",
      "value": "1.0",
      "status": "PASS|WARNING|FAIL",
      "message": "Deterministic rule-based check result",
      "ruleReference": "FS-RULE-006"
    },
    {
      "parameter": "MycoplasmaTest",
      "value": "0",
      "status": "PASS|WARNING|FAIL",
      "message": "Deterministic rule-based check result",
      "ruleReference": "FS-RULE-007"
    },
    {
      "parameter": "EndotoxinsEUPerDose",
      "value": "2.0",
      "status": "PASS|WARNING|FAIL",
      "message": "Deterministic rule-based check result",
      "ruleReference": "FS-RULE-008"
    },
    {
      "parameter": "VectorCopyNumber",
      "value": "2.5",
      "status": "PASS|WARNING|FAIL",
      "message": "Deterministic rule-based check result",
      "ruleReference": "FS-RULE-009"
    },
    {
      "parameter": "PotencyIFNg_pg_ml",
      "value": "1500.0",
      "status": "PASS|WARNING|FAIL",
      "message": "Deterministic rule-based check result",
      "ruleReference": "FS-RULE-010"
    },
    {
      "parameter": "PatientID",
      "value": "PAT-12345",
      "status": "PASS|WARNING|FAIL",
      "message": "Deterministic rule-based check result",
      "ruleReference": "FS-RULE-011"
    }
  ],
  "criticalFindings": [],
  "warnings": [],
  "audit": {
    "inputHash": "sha256:<calculated at runtime>",
    "rulesVersion": "<utility executable version>",
    "documentation": "Tisagenlecleucel_CellTherapyReleaseQualityChecker.documentation.html"
  }
}

Traceability matrix

URS	FS	Test	Evidence
URS-001	FS-001, FS-002	OQ-001	Verify execution and import of valid input.csv.
URS-002	FS-005, FS-006	OQ-004	Repeat the same dataset and compare output.json.
URS-003	FS-003, FS-004, FS-011	OQ-002, OQ-003	Verify missing columns and invalid types.
URS-004	FS-005, FS-006	OQ-004, PQ-001	Verify critical deviations on real/boundary data.
URS-005	FS-007, FS-009	OQ-005	Verify JSON schema and downstream-system suitability.
URS-006	FS-008	OQ-006	Verify identifiers and audit metadata.
URS-007	FS-008, FS-011	IQ-001, OQ-007	Verify documentation completeness and control evidence.
URS-008	FS-005, FS-008, FS-010	PQ-002	Verify review workflow and no replacement of QA decision.

IQ/OQ/PQ test scenarios

ID	Scenario	Expected result
IQ-001	Verify executable, input.csv, documentation and checksum availability.	Delivery set is complete; version is recorded.
OQ-001	Valid sample row from input.csv.	PASS or acceptable WARNING according to rules.
OQ-002	Remove a mandatory CSV column.	Schema error or FAIL with missing-column reference.
OQ-003	Place a non-numeric value into a numeric field.	Type-conversion error with row/field reference.
OQ-004	Set a critical parameter outside the limit.	FAIL and critical finding.
OQ-005	Verify output.json structure.	All mandatory sections are present and JSON is valid.
OQ-006	Verify batch/sample traceability.	Input and result identifiers match.
OQ-007	Verify fallback/decomposition for combined APIs.	Component checks are explicitly documented.
PQ-001	Verify 3–5 real user batches/samples.	Result is confirmed by QC/QA review.
PQ-002	Verify deviation workflow and manual QA decision.	Utility supports review but does not replace approved decision.

QA/QC and change control

Do not rename columns without updating validator, documentation and test set.
Retain input.csv, output.json, executable version and checksum.
Before production use, perform IQ/OQ/PQ or equivalent CSV/CSA verification.
Critical limits shall be verified against the approved specification, registration dossier and local SOPs.
For combination products, document whether the specialized FDC utility or fallback component checks were used.
The utility provides structured QC decision support; final release decision remains with QA/QP and approved procedures.

Included in packages

Biopharmaceuticals Core QC Suite

Focused QC utility package for biologic products: HCP, mAbs, biosimilars, proteins/peptides, sterility, endotoxins and key release checks.

Open

Biopharmaceuticals Extended QC Suite

Extended QC utility coverage for mAbs, biosimilars, proteins, insulins, vaccines, mRNA/LNP, HCP, sterile release, microbiology, water, cleanroom and stability workflows.

Open

Global API & Biosimilars QC Suite

Package for high-demand global APIs, generics and biosimilars, including fixed-dose combinations and biological products.

Open

Immunology QC Suite

QC utility package for immunology: monoclonal antibodies, biosimilars, immunomodulators, immunosuppressants, ELISA/SPR, HCP, protein characterization, sterility and pyrogen/release checks.

Open

World API Extension QC Suite

Extended package for 130 additional high-demand APIs and biological products prepared as a market-coverage backlog.

Open